A fundamental question is how to detect likely successful anticancer
treatments based on nanotechnology. We confront this question here by
analysing the trajectories of nanotechnologies applied to path-breaking
cancer treatments, which endeavour to pinpoint ground-breaking and
fruitful directions in nanomedicine. Results tend to show two main
technological waves of cancer treatments by nanotechnology applications.
The early technological wave in the early 2000s was embodied in some
types of chemotherapy agents with a broad spectrum, while after 2006 the
second technological wave appeared with new nanotechnological
applications in both chemotherapy agents and molecular target therapy.
The present study shows new directions of nanotechnology-based
chemotherapy and molecular cancer therapy in new treatments for breast,
lung, brain and colon cancers. A main finding of this study is the
recognition that, since the late 2000s, the sharp increase of several
technological trajectories of nanotechnologies and anticancer drugs
seems to be driven by high rates of mortality of some types of cancers
(e.g. pancreatic and brain) in order to find more effective anticancer
therapies that increase the survival of patients. The study also shows
that global research leaders specialize in nanotechnology applications
for specific cancers (e.g. Switzerland in prostate cancer, Japan in
colon cancer, China in ovarian cancer and Greece in pancreatic cancer).
These ground-breaking technological trajectories are paving new
directions in biomedicine and generating a revolution in clinical
practice that may lead to more effective anticancer treatments in the
Keywords: Nanotechnology, Nanoscience, Biomedicine, Nanomedicine, Target Therapy, Chemotherapy, Cancer, Bibliometrics, Publications, Technological Trajectories.
JEL classificaton: C89; O30, C53, I10;
Mathematics Susbject Classification (MSC2010): 91; 92